Company | Location | Investment | Company Focus And Technology |
(C$, 000) | |||
AnorMed Inc.* | Vancouver, | 720** | Research into therapeutics that use inorganic com- |
British Columbia | pounds | ||
ApoptoGen Inc.* | Ottawa, Ontario | 1,000** | Genetic research focusing on apoptosis |
BeaconEye Inc. | Toronto | 1,053** | Laser vision correction facilities |
Biostar Inc.* | Saskatoon, | 1,200 | Vaccines and therapeutics for animal and human |
Saskatchewan | health | ||
Drug Royalty Corp. | Toronto | 535** | Acquires royalty interests in pharmaceuticals |
Exogen | Montreal | 417 | Novel products for neuronal protection and cancer |
Neurosciences Inc.* | |||
GeminX | Montreal | 1,500 | Therapeutics for cancer and viral infections |
Biotechnologies Inc.* | |||
GenSci Regeneration | Toronto | 5,893** | Development of bioimplants and bone and tissue |
Sciences Inc. | regeneration products | ||
HRG Health | Calgary, Alberta | 2,000 | Health care facility providing short-term procedures |
Resource Group* | |||
LIFE Imaging | London, Ontario | 1,320** | 3-D ultrasound imaging systems |
Systems Inc.* | |||
Microbix | Toronto | 3,000 | Generic biotechnology products |
Biosystems Inc. | |||
Morphometrix | Toronto | 500 | Automated analytical system for Pap smear tests |
Technologies Inc.* | |||
Neuromotion Inc.* | Edmonton, Alberta | 1,250** | Functional and therapeutic electrical stimulating |
devices | |||
Nova Molecular | Montreal | 500** | Drug efficacy profiling assays for central |
Inc.* | nervous system disorders | ||
PhageTech Inc.* | Montreal | 250 | Novel antimicrobial therapeutics |
Phytogen Life | Vancouver | 3,981 | Producer of paclitaxel |
Sciences Inc.* | |||
StressGen/ | Victoria, | 10,000 | Gene therapy for cancer using stress proteins |
Genzyme Partnership | British Columbia | ||
Synapse | Vancouver | 50** | Alzheimer's disease diagnostic |
Technologies Inc.* | |||
Systems | Toronto | 5,000 | Computer software for transactions processing in |
Xcellence Inc. | health care organizations | ||
TerraGen Diversity | Vancouver | 1,500** | Novel compounds from previously unculturable |
Inc.* | microbes | ||
Tm Biopharma Corp. | Toronto | 1,750 | DNA tests, immunoassays and biochips |
UltraVision Inc. | Calgary | 1,000** | Proprietary contact lenses |
University Medical | Toronto | 1,500** | Early-stage financing for research projects |
Discoveries Inc.* | |||
Xillix Technologies | Richmond, | 5,000 | Fluorescence medical imaging devices for the early |
Corp. | British Columbia | detection of cancer | |
TOTAL FINANCING: | C$51.41M | ||
NOTES: | |||
* Private companies are indicated with an asterisk. | |||
** Follow-on financing | |||
Amounts are quoted in Canadian dollars. The exchange rate on 12/22/97 was C$1.43/US$1. | |||
Source: CMDF Annual Report 1997 |